Skip to Main Content

Author Details

Rebecca Pulk
Yale School of Medicine
2005
21
14
Richard Andrew Taylor (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36458283Pharmacogenomics driven decision support prototype with machine learning: A framework for improving patient care.Front Big Data2022
34230910Pharmacists leadership in a medication shortage response: Illustrative examples from a health system response to the COVID-19 crisis.J Am Coll Clin Pharm2021
33788846Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection.PLoS One2021
34125206An Integrated Approach to Deploy Panel-Based Pharmacogenetic Testing and Clinical Decision Support.J Appl Lab Med2021
32710774Dynamic pharmacy leadership during the COVID-19 crisis: Optimizing patient care through formulary and drug shortage management.Am J Health Syst Pharm2020
32743602Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection.medRxiv2020
30499100Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.Clin Pharmacol Ther2019
29316365Developing Pharmacogenomic Reports: Insights from Patients and Clinicians.Clin Transl Sci2018
29634876ProvenCare-Psoriasis: A disease management model to optimize care.Dermatol Online J2018
29572311Utilizing big data to provide better health at lower cost.Am J Health Syst Pharm2018
26067485Multigene predictors of tacrolimus exposure in kidney transplant recipients.Pharmacogenomics2015
23642482Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.Bioorg Med Chem Lett2013
238704302-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.Bioorg Med Chem Lett2013
23659214Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.J Med Chem2013
22335519Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.J Med Chem2012
23107482Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.Bioorg Med Chem Lett2012
22698084Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.J Med Chem2012
21117080A new regulatory switch in a JAK protein kinase.Proteins2011
19402633A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.J Med Chem2009
19703768Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).Bioorg Med Chem Lett2009
15799959Differential inhibition of inducible T cell cytokine secretion by potent iron chelators.J Biomol Screen2005
  • 1 - 21 of 21

Recommended Authors

Department of Pharmacotherapy and Translational Research, University of Florida
Career Start Year 2019
Number of shared co-authors 0
Icahn School of Medicine at Mount Sinai
Career Start Year 2014
Number of shared co-authors 3
Harvard T.H. Chan School of Public Health
Career Start Year 2014
Number of shared co-authors 0
Center for Individualized Medicine, Mayo Clinic
Career Start Year 2013
Number of shared co-authors 0
Vanderbilt University Medical Center
Career Start Year 2012
Number of shared co-authors 1
Department of Pharmacy Practice, 2University of Kansas School of Pharmacy
Career Start Year 2012
Number of shared co-authors 0
Mission Health Personalized Medicine & Pharmacogenomics Program
Career Start Year 2011
Number of shared co-authors 2
Stanford University
Career Start Year 2010
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 2009
Number of shared co-authors 2
Columbia Universtiy College of Physicians and Surgeons
Career Start Year 2009
Number of shared co-authors 2
Georgetown University Medical Center
Career Start Year 2006
Number of shared co-authors 1
Vanderbilt University School of Medicine
Career Start Year 2005
Number of shared co-authors 3
Harvard Medical School
Career Start Year 2005
Number of shared co-authors 0
Harvard Medical School and the Harvard Pilgrim Health Care Institute
Career Start Year 2004
Number of shared co-authors 1
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2004
Number of shared co-authors 2
St. Jude Children's Research Hospital Memphis
Career Start Year 2003
Number of shared co-authors 3
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 7
12328Vanderbilt University Medical Center
Career Start Year 2001
Number of shared co-authors 1
Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center
Career Start Year 2001
Number of shared co-authors 0
Vanderbilt University Medical Center
Career Start Year 2001
Number of shared co-authors 5
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 3
Yale School of Medicine
Career Start Year 1999
Number of shared co-authors 7
Department of Pharmacotherapy & Translational Research, University of Florida
Career Start Year 1999
Number of shared co-authors 3
University of Washington
Career Start Year 1997
Number of shared co-authors 2
Department of Pharmacy, Boston Children's Hospital
Career Start Year 1996
Number of shared co-authors 2
University of Pennsylvania Perelman School of Medicine
Career Start Year 1996
Number of shared co-authors 2
Institute of General Practice and Family Medicine, University Hospital
Career Start Year 1996
Number of shared co-authors 2
Harvard Medical School and Harvard Pilgrim Health Care Institute
Career Start Year 1995
Number of shared co-authors 1
University of Illinois Chicago
Career Start Year 1989
Number of shared co-authors 0
The University of New Mexico
Career Start Year 1977
Number of shared co-authors 0

Collaborators

Yale University School of Medicine
Co-authored papers 3
Yale University
Co-authored papers 3
Yale University
Co-authored papers 2
Yale New Haven Hospital
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Co-authored papers 2
Texas A&M University
Co-authored papers 2
Instituto Goncalo Moniz, Yale School of Public Health
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Beth Israel Deaconess Medical Center
Co-authored papers 2
Center for Outcomes Research and Evaluation, Yale New Haven Hospital
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Yale University School of Medicine
Co-authored papers 2
Yale University
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Yale University
Co-authored papers 2
Yale University School of Medicine
Co-authored papers 2
Department of Microbial Pathogenesis Yale University New Haven
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Co-authored papers 1
Pennsylvania State University, University Park
Co-authored papers 1
National Human Genome Research Institute, National Institutes of Health
Co-authored papers 1
Technical University of Munich (TUM)
Co-authored papers 1
Vanderbilt University Medical Center
Co-authored papers 1
Research Institute
Co-authored papers 1
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital
Co-authored papers 1
Yale University
Co-authored papers 1
Yale University School of Medicine
Co-authored papers 1
Yale New Haven Health System and Yale School of Medicine.
Co-authored papers 1